Earlier this week, The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its enactment. As stated previously, these claims are unequivocally false and last night The Washington Post issued a correction clarifying that PhRMA did not take a position on the legislation.
Recently, PhRMA has taken a number of steps to address the opioid crisis, such as announcing its support for a 7-day script limit on opioids for acute pain and launching a new partnership with the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) to bring new non-opioid therapies to market for patients who need them.
We will continue to work with other stakeholders to fight this terrible epidemic.
Holly Campbell
Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines.
Holly Campbell
More oversight needed of unapproved medicines that threaten patients’ health
Florida’s importation plan puts patients in danger
Three things to know about the accelerated approval pathway
Why drug importation is bad for Americans
PhRMA submits comments on FDA’s proposed rule on drug importation
Drug importation: An old idea that is still a bad idea
What they’re saying: Safety is top concern for recent drug importation proposal
ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals
PhRMA responds to Florida’s request for information on drug importation
PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients
Look at the facts. Drug importation is dangerous.
Combatting Opioid Abuse: Joint Partnership with the Rx Abuse Leadership Initiative and The National Sheriffs’ Association
Securely dispose of your unwanted medicines on National Take Back Day
PhRMA response to Washington Post and 60 Minutes stories
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Protect your health: Important disaster preparedness tips for Harvey and Irma
PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis
Opportunities to build upon enhanced competition for medicines in the marketplace
A critical opportunity to prevent prescription drug abuse
Former law enforcement officials raise concerns with drug importation proposals
Resources for understanding the dangers of drug importation
How drug importation schemes could increase U.S. law enforcement burdens
Case Study: How one online pharmacy knowingly endangered U.S. consumers
Why drug importation threatens patient safety
Fact Check Friday: The truth about drug importation and patient safety
What you don’t know about importation from Canada
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
The Washington Post retracts PhRMA claim in opioid story
Rx Drug Abuse
Prescription Drug Safety
The Washington Post retracts PhRMA claim in opioid story
The Washington Post retracts PhRMA claim in opioid story